---
title: "Greensignal Bio Pharma Ltd (1275414) — Share Price, Financials & Analysis"
symbol: "1275414"
company: "Greensignal Bio Pharma Ltd"
canonical: "https://tapetide.com/stocks/1275414"
generated_at: "2026-10-13T11:00:59.213Z"
---

# Greensignal Bio Pharma Ltd (1275414)

Canonical page: https://tapetide.com/stocks/1275414

## Company

- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No

## About

Greensignal Bio Pharma Limited was incorporated on 21st November 2005 as a Private Limited Company. The Company changed its name to GreenSignal Bio Pharma Private Limited on 21st April 2016. The Company has been converted into Public Limited Company consequent to issue of revised Certificate of Incorporation dated 12th May 2016 by the Registrar of
Companies. The Company has been converted into Private Limited Company consequent to issue of revised
Certificate of Incorporation dated 29th December 2017 by the Registrar of Companies. The Company produces Life
Saving Vaccine, namely, BCG Vaccine.

## Latest Price

## Key Insights

### Strengths

- Debtor days have improved from 204 to 23.6 days.

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 11% | — | — |
| revenue growth | 2% | 24% | 14% |

## Financial Statements

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 27 | 30 | 29 | 13 | 28 | 13 | 25 | 25 |
| Expenses | 19 | 23 | 15 | 16 | 19 | 18 | 45 | 48 |
| Operating Profit | 8 | 7 | 14 | -3 | 9 | -5 | -20 | -23 |
| OPM % | 31 | 23 | 49 | -22 | 31 | -37 | -78 | -90 |
| Other Income | 0 | 0 | 2 | 2 | 0 | -4 | 0 | 1 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 7 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 8 | 8 |
| Profit before tax | 6 | 4 | 13 | -4 | 6 | -13 | -34 | -31 |
| Tax % | 37 | 29 | 24 | 2 | 16 | 19 | 6 | 4 |
| Net Profit | 4 | 3 | 10 | -4 | 5 | -15 | -36 | -32 |
| EPS in Rs | 0.93 | 0.76 | 2.59 | -1.12 | 1.4 | -3.96 | -9.37 | -8.37 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 |
| Reserves | 11 | 13 | 23 | 18 | 24 | 9 | -57 | -89 |
| Borrowings | 3 | 0 | 0 | 0 | 48 | 108 | 256 | 341 |
| Other Liabilities | 6 | 7 | 7 | 7 | 9 | 9 | 39 | 29 |
| Total Liabilities | 58 | 58 | 68 | 63 | 119 | 164 | 276 | 319 |
| Fixed Assets | 39 | 35 | 33 | 31 | 28 | 58 | 117 | 121 |
| CWIP | 0 | 0 | 0 | 0 | 45 | 45 | 46 | 102 |
| Investments | 0 | 8 | 12 | 0 | 0 | 2 | 0 | 1 |
| Other Assets | 19 | 16 | 22 | 32 | 46 | 59 | 113 | 95 |
| Total Assets | 58 | 58 | 68 | 63 | 119 | 164 | 276 | 319 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -1 | 12 | 4 | -11 | -2 | -26 | -123 | -1 |
| Cash from Investing Activity | -3 | 1 | -2 | 0 | -42 | -34 | -21 | -65 |
| Cash from Financing Activity | 0 | 3 | -5 | 12 | 48 | 59 | 142 | 74 |
| Net Cash Flow | -4 | 16 | -2 | 1 | 5 | 0 | -2 | 7 |
| Free Cash Flow | -4 | 14 | 3 | -11 | -2 | -59 | -141 | -13 |
| CFO/OP | 13 | 189 | 31 | 375 | -18 | 532 | 630 | 6 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 64 | 34 | 85 | 129 | 92 | 1 | 384 | 24 |
| Inventory Days | 548 | 113 | 551 | 404 | 255 | 259 | 356 | 382 |
| Days Payable | 97 | 63 | 69 | 50 | 81 | 79 | 674 | 357 |
| Cash Conversion Cycle | 515 | 85 | 567 | 482 | 267 | 180 | 65 | 48 |
| Working Capital Days | 151 | 75 | 188 | 668 | 455 | 1384 | 1156 | 826 |
| ROCE % | — | 9 | 24 | -7 | 8 | -6 | — | -11 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 5 / 8 / 6

### Moving Averages — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 60.66 | Sell |
| EMA (10) | 59.54 | Sell |
| SMA (20) | 65.36 | Sell |
| EMA (20) | 64.51 | Sell |
| SMA (50) | — | Neutral |
| EMA (50) | — | Neutral |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 20.83 | Buy |
| MACD (12,26,9) | -6.14 | Sell |
| Stochastic (14,3,3) | 4.65 | Buy |
| ADX (14) | 46.66 | Buy |
| Williams %R (14) | -89.03 | Buy |
| ATR (14) | 3.83 | High Volatility |
| ROC (12) | -25.79 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 31.41 | Neutral |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-10-13T11:00:59.213Z.